Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7396 USD | -2.04% | -6.38% | +6.88% |
May. 14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
May. 09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 18.55M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.68
x | P/E ratio 2025 * |
-0.66
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.52% |
1 day | -2.04% | ||
1 week | -6.38% | ||
1 month | -41.30% | ||
3 months | -12.99% | ||
6 months | +7.19% | ||
Current year | +6.88% |
Managers | Title | Age | Since |
---|---|---|---|
John Celebi
CEO | Chief Executive Officer | 52 | 18-01-31 |
Erin Colgan
DFI | Director of Finance/CFO | 43 | 20-06-30 |
Chief Tech/Sci/R&D Officer | 51 | 19-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Ringo
CHM | Chairman | 78 | 22-03-07 |
John Celebi
CEO | Chief Executive Officer | 52 | 18-01-31 |
Bob Holmen
BRD | Director/Board Member | 60 | 16-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.7396 | -2.04% | 212,564 |
24-05-30 | 0.755 | -11.07% | 317,227 |
24-05-29 | 0.849 | +2.29% | 121,347 |
24-05-28 | 0.83 | +5.06% | 799,549 |
24-05-24 | 0.79 | -45.52% | 1,408,115 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.88% | 18.55M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SNSE Stock